<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Since the discovery of bcl-2 proto-oncogene in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, the protein product has been detected in a variety of <z:mpath ids='MPATH_458'>normal</z:mpath> tissues including skin, where it is expressed in basal keratinocytes </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies indicate that bcl-2 protein is detected in nonlymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> such as <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> and <z:mp ids='MP_0002038'>carcinomas</z:mp> of the lung and prostate </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigates the presence of bcl-2 protein in benign and malignant melanocytic <z:hpo ids='HP_0008069'>neoplasms of the skin</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemical analysis of bcl-2 protein expression was performed on 39 nevi and 60 <z:hpo ids='HP_0002861'>malignant melanomas</z:hpo>, including 21 metastases </plain></SENT>
<SENT sid="4" pm="."><plain>There was diffuse strong immunopositivity for bcl-2 protein in 100% of <z:e sem="disease" ids="C0027960" disease_type="Neoplastic Process" abbrv="">nevi</z:e> and 65% (43/60) of primary and metastatic <z:hpo ids='HP_0002861'>melanomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>bcl-2 protein was diffusely expressed in 67% (30/39) of primary <z:hpo ids='HP_0002861'>melanomas</z:hpo> and 54% (11/21) of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Although bcl-2 immunoreactivity was observed in <z:hpo ids='HP_0000001'>all</z:hpo> levels of primary cutaneous <z:hpo ids='HP_0002861'>malignant melanomas</z:hpo>, in 43% (9/21) of deep <z:hpo ids='HP_0002861'>melanomas</z:hpo> (Clark level &gt; or = III), and 100% (7/7) of thick <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (thickness &gt; or = 4.00 mm), there was focal loss of immunoreactivity </plain></SENT>
<SENT sid="7" pm="."><plain>Metastatic <z:hpo ids='HP_0002861'>melanomas</z:hpo> showed focal loss of bcl-2 expression in 10% (2/21) of cases and total loss of bcl-2 protein in 39% (8/21) </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude from our results that bcl-2 protein is expressed by benign and malignant <z:mpath ids='MPATH_358'>melanocytic tumors</z:mpath> of the skin, but there is loss of bcl-2 protein expression with increasing <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
</text></document>